Erste Asset Management GmbH Decreases Position in Amgen Inc. $AMGN

Erste Asset Management GmbH lowered its position in Amgen Inc. (NASDAQ:AMGN) by 21.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,162 shares of the medical research company’s stock after selling 25,403 shares during the quarter. Erste Asset Management GmbH’s holdings in Amgen were worth $25,269,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. West Family Investments Inc. increased its holdings in Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares in the last quarter. TAGStone Capital Inc. grew its position in shares of Amgen by 0.8% in the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the last quarter. BBR Partners LLC increased its stake in shares of Amgen by 0.5% during the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after purchasing an additional 32 shares in the last quarter. JFS Wealth Advisors LLC raised its position in shares of Amgen by 3.2% during the 3rd quarter. JFS Wealth Advisors LLC now owns 1,070 shares of the medical research company’s stock worth $302,000 after purchasing an additional 33 shares during the last quarter. Finally, Wealth Quarterback LLC lifted its stake in Amgen by 1.6% in the 3rd quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock valued at $624,000 after buying an additional 34 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen hit an all-time intraday high, reflecting strong investor demand and momentum that likely supported upward price pressure earlier in the session. Amgen stock hits all-time high
• Positive Sentiment: Amgen is featured in dividend-stock roundup articles, which can attract long-term income-focused buyers and support demand for shares given its yield and payout profile. Got $10,000? Put It in These Dividend Stocks Now
• Neutral Sentiment: Commentary pieces note Amgen has outpaced the Dow over the past year, providing a positive performance backdrop — but analysts remain cautious, suggesting upside may be tempered by valuation and execution risks. Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Legislative risk: S.3847 (Stop Corporate Inversions Act of 2026) was flagged as potentially relevant to multinationals including AMGN; the bill would tighten rules around inversion tax treatment — a longer-term policy item to monitor but not an immediate earnings driver. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported spikes in short interest appear in the feed but show zero shares/NaN in the figures — this looks like a data or reporting error rather than a meaningful change in positioning; still worth checking official exchange short-interest releases for confirmation.
• Negative Sentiment: A small institutional holder (Bradley Foster & Sargent) trimmed its position (~1,336 shares), a minor selling signal that may slightly contribute to sell-side flow but is not materially large versus Amgen’s market cap and average volume. Bradley Foster & Sargent Inc. CT Sells 1,336 Shares

Amgen Stock Down 1.3%

AMGN opened at $379.33 on Friday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $387.49. The business has a 50-day moving average of $347.68 and a two-hundred day moving average of $318.76. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The stock has a market capitalization of $204.48 billion, a price-to-earnings ratio of 26.66, a price-to-earnings-growth ratio of 3.81 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the firm posted $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Scotiabank began coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Finally, Truist Financial lifted their price target on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.